The FDA has approved Epclusa (Gilead), a fixed-dose combination of sofosbuvir (Sovaldi) and velpatasvir, a new direct-acting antiviral agent, for oral treatment of chronic hepatitis C virus (HCV) infection. Epclusa is the first oral combination to be approved for treatment of all six major HCV genotypes.
The prevalence of HCV genotypes in the US is about 75% for genotype 1, 20-25% for genotypes 2 and 3, and <2% for genotypes 4, 5, and 6 combined. Genotype testing is recommended to determine the optimal treatment regimen.1
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C. JAMA. 2017;317(6):639–640. doi:10.1001/jama.2016.12279
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: